Medtronic Plc (MDT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
116
About the Report
About the Report
Summary
Medtronic Plc (Medtronic), formerly Medtronic Inc, is a medical technology company that designs, develops, manufactures and markets a wide range of medical devices and solutions for the treatment of heart failure; heart valve disorders; diseases of the coronary artery; aortic; peripheral vascular; venous renal and neurological diseases; spine and musculoskeletal disorders; and diseases of the ear, nose and throat. It also provides biologic solutions for the orthopedic and dental markets. In the US, the company sells its products through direct sales force, and in other countries, through direct sales representatives and independent distributors. It serves hospitals, third-party healthcare providers, clinics, institutions including governmental health care programs, distributors, and group purchasing organizations in Asia Pacific, Europe, the Americas, the Middle East and Africa. Medtronic is headquartered in Dublin, Ireland.
Medtronic Plc (MDT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Medtronic Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Medtronic Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Medtronic Plc, Medical Devices Deals, 2012 to YTD 2018 12
Medtronic Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Medtronic Plc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Given Imaging Acquires SmartPill GI Monitoring Assets From SmartPill For USD 6 Million 17
Venture Financing 19
Semma Therapeutics Raises USD114 Million in Series B Financing 19
MD Start Secures USD11.5 Million in Venture Funding 21
Semma Therapeutics Raises USD44 Million in Series A Financing 22
AcuFocus Raises USD21 Million in Venture Financing 23
Sapheon Raises USD3.5 Million in Venture Financing 25
Sapheon Raises USD 20 Million In Series B Financing 26
Intersect ENT Raises USD 30 Million In Series D Financing 27
Sapheon Raises USD3.1 Million in Venture Financing 29
Visualase Secures USD5.2 Million in Series B Funding 30
Sapheon Raises USD1.3 Million in Venture Financing 31
Partnerships 32
Sanofi Enters into Co-Development Agreement with Medtronic 32
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 33
Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 34
Medtronic Plans To Enter Into Agreement With Pharma Companies For Alzheimer's 35
Debt Offering 36
Medtronic Raises USD4 Billion in Private Placement of 3.5% Notes Due 2025 36
Medtronic Raises USD2.5 Billion in Private Placement of 4.375% Notes Due 2035 37
Medtronic Raises USD1 Billion in Private Placement of Notes Due 2018 38
Medtronic Raises USD4 Billion in Private Placement of 4.625% Notes Due 2045 39
Medtronic Raises USD500 Million in Private Placement of Notes Due 2020 40
Medtronic Raises USD2.5 Billion in Private Placement of 3.15% Notes Due 2022 41
Medtronic Raises USD2.5 Billion in Private Placement of 2.5% Notes Due 2020 42
Medtronic Completes Public Offering Of Notes Due 2017 For USD 250 Million 43
Medtronic Completes Public Offering Of Notes Due 2044 For USD 650 Million 45
Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For USD 250 Million 47
Medtronic Completes Public Offering Of Notes Due 2024 For USD 850 Million 49
Covidien Completes Public Offering Of Notes Due 2023 For USD 750 Million 51
Covidien Completes Private Placement Of Notes Due 2018 For USD 300 Million 53
Covidien Completes Private Placement Of Notes Due 2023 For USD 600 Million 54
Medtronic Completes Public Offering Of Notes Due 2043 For USD 750 Million 55
Medtronic Completes Public Offering Of Notes Due 2023 For USD 1.25 Billion 57
Medtronic Completes Public Offering Of Notes Due 2018 For USD 1 Billion 59
Covidien Completes Public Offering Of Senior Notes Due 2022 For USD 650 Million 61
Covidien Completes Public Offering Of Senior Notes Due 2015 For USD 600 Million 62
Medtronic Completes Public Offering Of 3.125% Senior Notes Due 2022 For USD 675 Million 63
Medtronic Completes Public Offering Of 4.5% Senior Notes Due 2042 For USD 400 Million 65
Asset Transactions 67
Spectranetics Acquires Stellarex from Covidien for USD30 Million 67
Capricor Therapeutics Acquires Intellectual Property Rights to Natriuretic Peptides from Medtronic 68
Covidien Plans to Divest Vascular Therapies Business 69
Acquisition 70
Medtronic Acquires Diabeter 70
Medtronic Acquires Covidien for USD49.9 Billion 71
Medtronic May Acquire Smith & Nephew 73
Medtronic Plc-Key Competitors 74
Medtronic Plc-Key Employees 75
Medtronic Plc-Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 88
Strategy And Business Planning 88
Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 88
Financial Announcements 89
Aug 21, 2018: Medtronic announces first quarter financial results 89
May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 91
Feb 20, 2018: Medtronic Reports Third Quarter Financial Results 93
Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 96
Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 99
Aug 22, 2017: Medtronic Reports First Quarter Financial Results 100
May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 103
Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 106
Corporate Communications 109
Aug 01, 2018: Medtronic announces Paurvi Bhatt as president of Medtronic Foundation 109
May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 110
Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 111
Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 112
Product News 113
Jun 22, 2018: Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available 113
Other Significant Developments 114
Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 114
Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 115
Appendix 116
Methodology 116
About GlobalData 116
Contact Us 116
Disclaimer 116
List of Figure
List of Figures
Medtronic Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Medtronic Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Medtronic Plc, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Medtronic Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Medtronic Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Medtronic Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Medtronic Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Medtronic Plc, Medical Devices Deals, 2012 to YTD 2018 12
Medtronic Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Given Imaging Acquires SmartPill GI Monitoring Assets From SmartPill For USD 6 Million 17
Semma Therapeutics Raises USD114 Million in Series B Financing 19
MD Start Secures USD11.5 Million in Venture Funding 21
Semma Therapeutics Raises USD44 Million in Series A Financing 22
AcuFocus Raises USD21 Million in Venture Financing 23
Sapheon Raises USD3.5 Million in Venture Financing 25
Sapheon Raises USD 20 Million In Series B Financing 26
Intersect ENT Raises USD 30 Million In Series D Financing 27
Sapheon Raises USD3.1 Million in Venture Financing 29
Visualase Secures USD5.2 Million in Series B Funding 30
Sapheon Raises USD1.3 Million in Venture Financing 31
Sanofi Enters into Co-Development Agreement with Medtronic 32
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 33
Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 34
Medtronic Plans To Enter Into Agreement With Pharma Companies For Alzheimer's 35
Medtronic Raises USD4 Billion in Private Placement of 3.5% Notes Due 2025 36
Medtronic Raises USD2.5 Billion in Private Placement of 4.375% Notes Due 2035 37
Medtronic Raises USD1 Billion in Private Placement of Notes Due 2018 38
Medtronic Raises USD4 Billion in Private Placement of 4.625% Notes Due 2045 39
Medtronic Raises USD500 Million in Private Placement of Notes Due 2020 40
Medtronic Raises USD2.5 Billion in Private Placement of 3.15% Notes Due 2022 41
Medtronic Raises USD2.5 Billion in Private Placement of 2.5% Notes Due 2020 42
Medtronic Completes Public Offering Of Notes Due 2017 For USD 250 Million 43
Medtronic Completes Public Offering Of Notes Due 2044 For USD 650 Million 45
Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For USD 250 Million 47
Medtronic Completes Public Offering Of Notes Due 2024 For USD 850 Million 49
Covidien Completes Public Offering Of Notes Due 2023 For USD 750 Million 51
Covidien Completes Private Placement Of Notes Due 2018 For USD 300 Million 53
Covidien Completes Private Placement Of Notes Due 2023 For USD 600 Million 54
Medtronic Completes Public Offering Of Notes Due 2043 For USD 750 Million 55
Medtronic Completes Public Offering Of Notes Due 2023 For USD 1.25 Billion 57
Medtronic Completes Public Offering Of Notes Due 2018 For USD 1 Billion 59
Covidien Completes Public Offering Of Senior Notes Due 2022 For USD 650 Million 61
Covidien Completes Public Offering Of Senior Notes Due 2015 For USD 600 Million 62
Medtronic Completes Public Offering Of 3.125% Senior Notes Due 2022 For USD 675 Million 63
Medtronic Completes Public Offering Of 4.5% Senior Notes Due 2042 For USD 400 Million 65
Spectranetics Acquires Stellarex from Covidien for USD30 Million 67
Capricor Therapeutics Acquires Intellectual Property Rights to Natriuretic Peptides from Medtronic 68
Covidien Plans to Divest Vascular Therapies Business 69
Medtronic Acquires Diabeter 70
Medtronic Acquires Covidien for USD49.9 Billion 71
Medtronic May Acquire Smith & Nephew 73
Medtronic Plc, Key Competitors 74
Medtronic Plc, Key Employees 75
Medtronic Plc, Other Locations 77
Medtronic Plc, Subsidiaries 77
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.